began experiencing increased difficulty with mucosal bleeding, which prompted frequent platelet transfusions. At 4. years, he had a major gastrointestinal bleed, followed Immunosuppressive therapy is commonly used in the management of autoimmune disorders. As marrow-1 month later by an intracranial hemorrhage. He required transient ventilator support, but eventually regained full derived lymphocytes appear to play a key role in these diseases, lymphoid ablation followed by replacement neurologic function. Direct (DAT) and indirect (IAT) Coombs evaluations were always 3+ positive. Due to the with autologous or allogeneic stem cells may be a therapeutic option. We report a 5-year-old boy with severe severe and refractory nature of his disease, the option of novel therapy with bone marrow transplantation was Evans syndrome which consists of immune thrombocytopenia and Coombs-positive hemolytic anemia. He was pursued. HLA typing of the family, and a search of the unrelated rendered into complete remission with marrow ablation followed by rescue with an HLA-identical sibling cord marrow donor registries, did not identify an appropriate donor, but DNA-based typing for HLA-A, -B, -DRB1 of blood transplant. He unexpectedly died 9 months following transplant from acute hepatic failure of the amniotic fluid of a sibling fetus, of 6 months gestational age, revealed a complete HLA match. Cord blood was harunknown etiology. Keywords: cord blood transplant; Evans syndrome; autovested and cryopreserved at delivery, and the patient was started on myelo-and immuno-ablation 13 days later with immune disease TBI 225 cGy once daily for 6 days (total dose 1350 cGy), then cyclophosphamide 60 mg/kg once daily i.v. for 2 days (total dose 120 mg/kg), followed by cord blood thawing Utah Unique Patient No. 263 was the product of a normal and infusion (0.385 × 10 8 nucleated cells/kg patient, pregnancy, labor and delivery. He was apparently healthy 0.096 × 10 6 CD34 + cells/kg patient). Acute graft-versusuntil 5 months of age when he presented with Coombshost disease (GVHD) prophylaxis was with cyclosporine, positive hemolytic anemia and thrombocytopenia. Bone with G-CSF initiated on day +1. The patient engrafted with marrow evaluation revealed a hypercellular marrow with an ANC greater than 0.5 × 10 9 /l on day +16. On day +17, normal myeloid and erythroid elements, but increased he developed symptoms of acute GVHD, with temperatures megakaryocytes. No viral infection could be identified. The of up to 40°C, skin rash that on biopsy was consistent with diagnosis of Evans syndrome was made, and he was sub-GVHD, and severe pulmonary insufficiency. He was intusequently treated with prednisone, intravenous immune bated for 2 days and treated with high-dose steroids, with globulin, 6-mercaptopurine and danazol, all with poor rapid resolution of symptoms. Platelet engraftment was response. Because of refractory thrombocytopenia, he delayed, with sustained platelets greater than 30 × 10 9 /l by underwent splenectomy at 9 months of age, with a transient day +170. He was platelet-independent from day +240, and rise in his platelet count to greater than 100 × 10 9 /l but with RBC independent from +210. Re-evaluation of his RBC a rapid fall to less than 20 × 10 9 /l. Over the next 4 years, antibody status revealed a DAT that was only microscopihe was treated with cyclosporine, azathioprine, combination cally positive by day +20, and negative on day +286. Antichemotherapy, anti-Rh antibody (anti-D) and 28-day cycles platelet antibodies were negative on day +115, and day of pulse methylprednisolone, vincristine, and intravenous +176. Figure 1 illustrates his transfusion requirements for immune globulin. The pulse therapy was most successful, the 9-month period just prior to, and following BMT. as it transiently increased his platelet count to greater than On day +286, the patient was admitted to the hospital 50 × 10 9 /l for 1 to 2 weeks. with acute onset of fulminant hepatic failure and coma folDespite frequent platelet counts of less than 20 × 10 9 /l, lowing a 2 day history of streptococcal pharyngitis, vomithe remained clinically stable until age 4 years, when he ing and malaise. Medications at the time of admission were amoxicillin, prophylactic trimethoprim-sulfamethoxazole and deferoxamine mesylate for transfusional iron overload.
/l. Over the next 4 years, antibody status revealed a DAT that was only microscopihe was treated with cyclosporine, azathioprine, combination cally positive by day +20, and negative on day +286. Antichemotherapy, anti-Rh antibody (anti-D) and 28-day cycles platelet antibodies were negative on day +115, and day of pulse methylprednisolone, vincristine, and intravenous +176. Figure 1 illustrates his transfusion requirements for immune globulin. The pulse therapy was most successful, the 9-month period just prior to, and following BMT. as it transiently increased his platelet count to greater than On day +286, the patient was admitted to the hospital 50 × 10 9 /l for 1 to 2 weeks. with acute onset of fulminant hepatic failure and coma folDespite frequent platelet counts of less than 20 × 10 9 /l, lowing a 2 day history of streptococcal pharyngitis, vomithe remained clinically stable until age 4 years, when he ing and malaise. Medications at the time of admission were amoxicillin, prophylactic trimethoprim-sulfamethoxazole and deferoxamine mesylate for transfusional iron overload. ment-related severe aplastic anemia (SAA). [3] [4] [5] Three of four patients from these early anecdotes died from transplantrelated complications. 3 Results from more recent series the patient's hepatic transminases were markedly elevated with serum aspartate aminotransferase (AST) of 410 IU/l have been more encouraging, with several reports of sustained remissions of underlying autoimmune diseases foland alanine aminotransferase (ALT) of 589 IU/l. Plasma ammonia, prothrombin time and partial thromboplastin lowing allogenic BMT. [4] [5] [6] [7] [8] McAllister et al 9 from our institution reported a patient with multiple sclerosis (MS) who times were also elevated with values of 263 mol/l, 20.7 s and Ͼ100 s, respectively, further reflecting severe hepatoreceived an HLA-matched sibling transplant for the treatment of chronic myelogenous leukemia. Her MS symptoms cellular injury. Gamma-glutamyltranspeptidase (GGT), total bilirubin and alkaline phosphatase were normal. The improved, and the MRI of her brain is stable to improved 1 year following transplant. Lowenthal et al 4 have sugpatient had no known history of antecedent liver disease, and values for hepatic aminotransferases were normal in gested that the preparative regimen of BMT may induce disease remission, and that this remission may be sustained the preceding month.
An infectious or toxic etiology for this patient's liver due to clonal elimination of effector cells. The etiology of this patient's fulminant hepatic necrosis failure was suspected, however all cultures for viral, bacterial and fungal pathogens were negative during his hospiis unknown. Further, the observed liver histology does not explain his clinical course. Although an infectious or toxic talization. Toxicology screening was also negative. As no clear etiology was present, liver biopsy was planned and the etiology is suspected, this has not been confirmed. Autoimmune diseases including chronic active hepatitis have patient was considered for liver transplantation. His coma deepened however, and he developed multisystem organ been associated with Evans syndrome. 1 This patient however did not have serologic or histologic evidence of autofailure. Life support was withdrawn, and the patient died 289 days following transplant.
immune hepatic disease. A multifactorial etiology for this patient's hepatic failure is more likely. Perhaps it was due At autopsy, the patient's liver biopsy was nondiagnostic. Patchy portal inflammation, focal centrilobular hemorrhage to an acute infection in the face of previously undetected hepatic compromise from iron overload, total parenteral and necrosis, and moderate steatosis were present. There was minimal siderosis. Further, hepatic tissue showed no nutrition and medications. Although this patient died unexpectedly, the cord blood evidence of specific toxins nor human herpes virus 6, cytomegalovirus, herpes simplex virus, adenovirus, bacteria or transplantation appeared successful in the treatment of his refractory Evans syndrome. Cyclosporine has been successfungus. After the patient's death, total antibody for hepatitis A virus was reactive, however IgG and IgM levels were fully used to treat autoimmune diseases including Evans syndrome in small series of patients. 10 This may have connot determined. It therefore cannot be concluded if an acute hepatitis A virus infection was present, or if IgG was tributed to this patient's remission. However, he had no evidence of response with cyclosporine pretransplant, and acquired from prior transfusions or intravenous immunoglobulin.
no evidence of disease recurrence 2 months after discontinuation of cyclosporine, and 4 months after discontinuation of prednisone. At the time of death, the patient was off all immunosuppression, and had complete resolution of Discussion his autoimmune disease. Platelet engraftment was delayed, but the patient was able to maintain an unsupported platelet Evans syndrome is often difficult to treat due to its chronic course characterized by remissions and exacerbations. 1 count of 80 × 10 9 /l from day +240, and antiplatelet antibodies were negative. The IAT became negative by day Often, the response to corticosteroids and splenectomy is
